Compare Enveric Biosciences Inc (ENVB) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Williams-Sonoma, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Williams-Sonoma, Inc. trades at $227.76 (market cap $26.24B). The key difference: Williams-Sonoma, Inc. is far larger — about 4932.3× Enveric Biosciences Inc's market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | WSM | |
|---|---|---|
Market Cap | $5.32M | $26.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $240.06 |
52-Week Low | $1.28 | $165.01 |
Enterprise Value | $408.82K | $27.08B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Williams-Sonoma (WSM) trades at $220.34, up 1.7% on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 13.81% net income margin and 54.01% ROE, though revenue has been volatile. Recent earnings have consistently beaten expectations, and the company maintains active brand collaborations and dividend payments.
The outlook is mixed; strong fundamentals and earnings beats support upside, but high valuation multiples and competitive pressures pose risks. Analyst consensus is a Hold with a $215.22 price target slightly below current levels, indicating cautious optimism tempered by valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
